Forte Biosciences, Inc. booked $36.0k in FY2019 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -192708.3% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.